PROK — PROKIDNEY CORP.

—
Nasdaq · Health Care · Biotechnology · CIK 1850270 ·
Last close
$1.10
Market Cap
$229.87M
52W High
$2.65
52W Low
$0.87
ADV30
1,367,041
Next earnings
2026-11-12
ProKidney Corp., a clinical-stage biotechnology company, engages in the development of cell therapies for the treatment of chronic kidney diseases in the United States. The company develops rilparencel, a cell therapy with autologous selected renal cells, which is in Phase III clinical trial for the treatment of advanced chronic kidney disease and type 2 diabetes. It is also involved in the development of cryopreserved versions of rilparencel, including REGEN-006 and REGEN-008 which are both in Phase III clinical trials; REGEN-002, REGEN-003, and REGEN-007 which are in Phase II clinical trials; and REGEN-004 which is Phase I clinical trial. The company was founded in 2015 and is headquartered in Winston-Salem, North Carolina.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 174,000 — -53,758,000 -35,592,000 210,279,000 81,355,000 33,304,000
Jun 2026 150,000 — -48,373,000 -28,422,000 249,016,000 74,868,000 26,178,000
Mar 2026 226,000 — -44,933,000 -20,037,000 292,784,000 101,895,000 29,680,000
Dec 2025 225,000 — -45,371,000 -19,231,000 335,574,000 108,537,000 34,781,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-141,167,000
Investing CF
$104,744,000
Financing CF
$26,351,000
CapEx
$-18,567,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.54
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-1,318,294,000
Inventory
—
Receivables
$956,000
ST Investments
$106,696,000
EBIT TTM
$-166,758,000
Pretax Income TTM
$-166,777,000
Interest Exp TTM
$19,000
Analysts
4

Yahoo Snapshot (yfinance, live)

Total Revenue
$775,000
EBITDA
$-185,907,008
Free Cash Flow
$-86,582,872
Enterprise Value
$1,164,281,856
Total Cash
$141,864,000
Total Debt
$3,253,000
Shares Out
208,975,486
Trailing EPS
$-0.50
Book Value
$-4.34
ROE
-73.4%
ROA
-42.9%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 893,000 -165,007,000 -68,986,000 335,574,000 34,781,000 -1,011,197,000 -120,117,000
Dec 2024 76,000 -183,676,000 -61,186,000 441,073,000 39,436,000 -994,954,000 -126,351,000
Dec 2023 0 -151,522,000 -35,468,000 420,552,000 29,216,000 -1,103,396,000 -90,069,000
Dec 2022 0 -153,007,000 -108,032,000 517,996,000 13,057,000 -1,096,616,000 -77,089,000

TTM Snapshot

Revenues TTM
$818,000
NetIncome TTM
$-84,159,000
OpCashFlow TTM
—
Assets (Latest)
$249,016,000
Forward EPS
$-0.77

Max Pain — expiry 2027-01-15 (volume-derived — Yahoo OI feed degraded)

max pain strike: $1.00 · spot: $1.04 · call volume: 202 · put volume: 92

Peers — same industry

TickerNameMarket CapLastDaily %
LXEO Lexeo Therapeutics, Inc. $234.24M $2.86 —
CABA Cabaletta Bio, Inc. $220.03M $1.02 —
PLX Protalix BioTherapeutics, Inc. $242.84M $2.88 —
IPSC Century Therapeutics, Inc. $248.79M $1.37 —
LCTX Lineage Cell Therapeutics, Inc. $206.36M $0.82 —

News headlines (Yahoo Finance, 1h cache)

ProKidney Names Farah Ali, M.D., M.S., Chief Medical Officer
2026-11-18 21:15 · Yahoo
ProKidney Corp. (PROK) Reports Q3 Loss, Misses Revenue Estimates
2026-11-12 22:05 · Yahoo
ProKidney Reports Third Quarter 2026 Financial Results and Business Highlights
2026-11-12 21:10 · Yahoo
ProKidney Targets Q2 2027 Phase III Readout as Rilparencel Enrollment Surpasses 500
2026-10-28 10:03 · Yahoo
ProKidney to Host Virtual KOL Event to Recap Mechanism of Action Data Presented at ASN Kidney Week and Provide a Corporate Update
2026-10-22 12:45 · Yahoo
ProKidney Announces Eight Abstracts Selected for Presentation at the American Society of Nephrology’s Kidney Week 2026
2026-10-22 12:00 · Yahoo
ProKidney (PROK) Nears A Pivotal Kidney Therapy Verdict
2026-09-11 05:28 · Yahoo
Why ProKidney (PROK) Is Building Its Bull Case Around Rilparencel’s Accelerated Approval Path
2026-06-17 15:16 · Yahoo
ProKidney Corp. (PROK) Reports Q1 Loss, Tops Revenue Estimates
2026-05-15 16:55 · Yahoo
ProKidney Reports First Quarter 2026 Financial Results and Business Highlights
2026-05-15 15:45 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.